FDA Grants Priority Review to Imfinzi for Gastric and GEJ Cancer Treatment

The U.S. Food and Drug Administration (FDA) has granted Priority Review status to Imfinzi (durvalumab) for the treatment of certain gastric and gastroesophageal junction (GEJ) cancers. This designation applies to patients with early-stage, resectable, and locally advanced cancers spanning stages 2 through 4a. The move reflects the potential of Imfinzi as a promising therapy for these cancer types. For detailed information, please log in or subscribe to access the full article.